Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: TG Therapeutics (TGTX), Insmed (INSM) and Solventum Corporation (SOLV)

Tipranks - Tipranks - Thu Apr 9, 5:54AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX), Insmed (INSM) and Solventum Corporation (SOLV).

Easter Sale - 70% Off TipRanks

TG Therapeutics (TGTX)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on TG Therapeutics, with a price target of $15.00. The company’s shares closed last Tuesday at $33.39.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 5.0% and a 49.9% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Recursion Pharmaceuticals, and Perspective Therapeutics. ;'>

TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $42.00.

See today’s best-performing stocks on TipRanks >>

Insmed (INSM)

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Insmed yesterday and set a price target of $212.00. The company’s shares closed last Tuesday at $163.03.

According to TipRanks.com, Skor is a 4-star analyst with an average return of 15.8% and a 61.2% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Monopar Therapeutics Inc, and Atea Pharmaceuticals. ;'>

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $214.71, implying a 31.9% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

Solventum Corporation (SOLV)

In a report released today, Travis Steed from Bank of America Securities maintained a Hold rating on Solventum Corporation, with a price target of $85.00. The company’s shares closed last Tuesday at $62.49.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 2.4% and a 48.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Solventum Corporation with a $91.50 average price target, which is a 45.1% upside from current levels. In a report issued on March 24, TipRanks – xAI also reiterated a Hold rating on the stock with a $70.00 price target.

Read More on TGTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).